Overview

TPC VS. GP Induced Chemotherapy Combined With Nimotuzumab and Toripalimab in the Treatment of Locally Advanced Nasopharyngeal Carcinoma

Status:
NOT_YET_RECRUITING

Trial end date:
2031-08-20

Target enrollment:

Participant gender:

Summary

We expect to conduct a clinical trial in high-risk locally advanced nasopharyngeal carcinoma patients to explore the efficacy and safety of sequential radical radiotherapy treatment after induction chemotherapy (TPC vs. GP) with combination therapy of nivolumab and triprolizumab.

Phase:

PHASE3

Details

Lead Sponsor:

Sun Yat-sen University

Treatments:

Capecitabine
Gemcitabine
nimotuzumab